Stockchase Research Editor: Michael O'Reilly AMGN just released earnings and the 12% increase in revenues and 5% increase in EPS were likely held back due to government mandates to focus health spending towards COVID-19 projects. The company is now benefitting from the release of new arthritis and metastatic colorectal cancer treatments. They also signed a deal to partner with Eli Lilly to manufacture a coronavirus antibody treatment, when it is ready. They pay a good dividend, backed by a 50% payout ratio. We would trade this with a stop-loss of $205 and a target of of $255 -- over 15% upside. Yield 2.91% (Analysts’ price target is $254.12)
Stockchase Research Editor: Michael O'Reilly AMGN just released earnings and the 12% increase in revenues and 5% increase in EPS were likely held back due to government mandates to focus health spending towards COVID-19 projects. The company is now benefitting from the release of new arthritis and metastatic colorectal cancer treatments. They also signed a deal to partner with Eli Lilly to manufacture a coronavirus antibody treatment, when it is ready. They pay a good dividend, backed by a 50% payout ratio. We would trade this with a stop-loss of $205 and a target of of $255 -- over 15% upside. Yield 2.91% (Analysts’ price target is $254.12)
Stockchase Research Editor: Michael O'Reilly NCR is a global leading point-of-sale and ATM software provider. Following recent earnings, it is trading at a PE of 6. With expectations of over 40% growth in EPS next year, this TOP PICK is good value. No doubt retail vendors have been impacted by the pandemic, however, the need for contact-less payment systems will only grow. Analysts at JP Morgan just upgraded the stock to overweight with a $27 target. We would trade this with a $18 stop-loss, looking to hit analyst targets -- over 30% upside. Yield 0% (Analysts’ price target is $27.00)
Stockchase Research Editor: Michael O'Reilly NCR is a global leading point-of-sale and ATM software provider. Following recent earnings, it is trading at a PE of 6. With expectations of over 40% growth in EPS next year, this TOP PICK is good value. No doubt retail vendors have been impacted by the pandemic, however, the need for contact-less payment systems will only grow. Analysts at JP Morgan just upgraded the stock to overweight with a $27 target. We would trade this with a $18 stop-loss, looking to hit analyst targets -- over 30% upside. Yield 0% (Analysts’ price target is $27.00)